1.045
0.95%
-0.005
전일 마감가:
$1.05
열려 있는:
$1.08
하루 거래량:
694.02K
Relative Volume:
0.14
시가총액:
$83.18M
수익:
-
순이익/손실:
$-117.23M
주가수익비율:
-0.7257
EPS:
-1.44
순현금흐름:
$-95.25M
1주 성능:
-17.46%
1개월 성능:
-28.28%
6개월 성능:
-72.04%
1년 성능:
-76.04%
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
명칭
Tenaya Therapeutics Inc
전화
415-865-2066
주소
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
TNYA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
1.04 | 83.18M | 0 | -117.23M | -95.25M | -1.44 |
VRTX
Vertex Pharmaceuticals Inc
|
439.80 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
680.29 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
663.27 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
275.25 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
121.37 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-06-10 | 개시 | William Blair | Outperform |
2023-11-30 | 개시 | Leerink Partners | Outperform |
2022-06-15 | 개시 | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc 주식(TNYA)의 최신 뉴스
Tenaya Therapeutics announces option repricing to retain staff - Investing.com
Here's Why Tenaya Therapeutics (NASDAQ:TNYA) Must Use Its Cash Wisely - Simply Wall St
Tenaya Therapeutics (TNYA) Stock Price, News & Analysis - MarketBeat
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Shares Sold by Jane Street Group LLC - Defense World
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $17.33 Average PT from Brokerages - MarketBeat
Brokerages Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) PT at $17.33 - Defense World
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Short Interest Update - MarketBeat
HC Wainwright Reiterates Buy Rating for Tenaya Therapeutics (NASDAQ:TNYA) - MarketBeat
Tenaya advances gene therapies for heart conditions By Investing.com - Investing.com Canada
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones - GlobeNewswire
Tenaya advances gene therapies for heart conditions - Investing.com
Tenaya Therapeutics Advances Gene Therapy Programs with Promising TN-201 Trial Progress - StockTitan
Analysts Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Price Target at $17.33 - MarketBeat
Geode Capital Management LLC Increases Holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Things To Consider Before Buying Tenaya Therapeutics Inc (NASDAQ: TNYA) - Stocks Register
Zhongzhi drops $3M in Gabaeron series A for stem cell AD therapy - BioWorld Online
Largest borrow rate increases among liquid names - TipRanks
State Street Corp Purchases 9,506 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Tenaya Therapeutics: TN-201 Isn't The Only Shot On Goal Targeting Heart Disease (TNYA) - Seeking Alpha
Short Interest in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Grows By 18.8% - MarketBeat
Reviewing Caribou Biosciences (NASDAQ:CRBU) & Tenaya Therapeutics (NASDAQ:TNYA) - Defense World
XTX Topco Ltd Has $95,000 Position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Tenaya Therapeutics (NASDAQ:TNYA) Earns Buy Rating from Chardan Capital - Defense World
Tenaya Therapeutics (NASDAQ:TNYA) Earns “Buy” Rating from HC Wainwright - Defense World
Tenaya Therapeutics (NASDAQ: TNYA) Senior Vice President Chihiro Saito Resigns: 8-K Filing - Defense World
Tenaya Therapeutics stock backed by H.C. Wainwright on TN-401 safety and protein expression gains - Investing.com
Tenaya Therapeutics (NASDAQ:TNYA) Receives "Buy" Rating from Chardan Capital - MarketBeat
Tenaya Therapeutics (NASDAQ:TNYA) Given "Buy" Rating at HC Wainwright - MarketBeat
Tenaya Stock Crashes as Cardio Gene Therapy Delivers Underwhelming Early-Stage Data - BioSpace
Tenaya Therapeutics stock hits 52-week low at $1.49 By Investing.com - Investing.com South Africa
Contrasting Tenaya Therapeutics (NASDAQ:TNYA) and Vaxart (NASDAQ:VXRT) - Defense World
Tenaya Therapeutics (NASDAQ:TNYA) & Big Cypress Acquisition (OTCMKTS:BCYP) Critical Comparison - Defense World
Tenaya reports positive early data on heart gene therapy By Investing.com - Investing.com Australia
Tenaya stock in selloff on gene therapy data (TNYA:NASDAQ) - Seeking Alpha
Tenaya Therapeutics announces executive departure - Investing.com
Tenaya Therapeutics stock hits 52-week low at $1.49 - Investing.com
Tenaya Therapeutics Reports Promising TN-201 Trial Results - TipRanks
Tenaya Therapeutics’ Senior VP Resigns for New Opportunity - TipRanks
Tenaya reports positive early data on heart gene therapy - Investing.com
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy - GlobeNewswire
Tenaya's Gene Therapy Shows Promise in Early Heart Disease Trial DataKey Clinical Results - StockTitan
Crude Oil Down Over 1%; US Industrial Production Declines In November - Benzinga
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 - The Manila Times
Tenaya Therapeutics to Unveil Groundbreaking Gene Therapy Data for Heart Disease Treatment - StockTitan
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 - GlobeNewswire
Fmr LLC Raises Stock Holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
Around the Helix: Cell and Gene Therapy Company Updates – December 11, 2024 - CGTLive™
Tenaya Therapeutics' SWOT analysis: gene therapy stock faces pivotal catalysts - Investing.com
Tenaya Therapeutics Inc (TNYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):